Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01249027 · ClinicalTrials.gov registry record
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
A clinical trial, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 2,605
- Enrollment target
NCT01249027 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 2,605 participants.
The verdict
NCT01249027 has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 2,605 participants
- Enrollment target
Study Summary
This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: * Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial use * Evaluate patient compliance to dual antiplatelet therapy (DAPT)
Interventions
- DEVICE XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,605 participants |
| Start Date | 2010-11 |
| Est. Completion | 2017-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01249027
The ClinicalTrials.gov registry entry for NCT01249027 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,605 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) is the first listed.
NCT01249027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01249027 about?
NCT01249027 is a clinical study titled "XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study". This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: * Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial...
What is the current status of trial NCT01249027?
This trial is currently completed. The enrollment target is 2,605 participants. The study started on 2010-11. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01249027?
The interventions under investigation include: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) (DEVICE).
Who is sponsoring clinical trial NCT01249027?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.